Stay updated on Pembrolizumab Combo in Ovary Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.

Latest updates to the Pembrolizumab Combo in Ovary Cancer Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedRevision: v3.4.2 was added and v3.4.1 removed; this is a minor UI revision with no impact on study content, eligibility, enrollment, or results. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.0%

- Check21 days agoChange DetectedRevision: v3.4.1 is now shown, replacing v3.4.0. No study content or eligibility criteria appear to be changed.SummaryDifference0.0%

- Check29 days agoChange DetectedThe changes add a Show glossary option and standardize metadata labels (Last Update Submitted that Met QC Criteria, No FEAR Act Data, Revision: v3.4.0) while removing older labels (Last Update Submitted that met QC Criteria, No FEAR Act data, Revision: v3.3.4). These updates do not alter core study content, eligibility, or results, and to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check36 days agoChange DetectedAdded related topics: Ovarian cancer and MedlinePlus Genetics to the page.SummaryDifference0.1%

- Check43 days agoChange DetectedAdded Revision: v3.3.4; removed related topics 'Ovarian cancer' and 'MedlinePlus Genetics', and removed 'Revision: v3.3.3'.SummaryDifference0.2%

- Check64 days agoChange DetectedNew Locations section added with Ohio and Wisconsin sites, replacing the previous separate Ohio Locations and Wisconsin Locations sections.SummaryDifference0.3%

Stay in the know with updates to Pembrolizumab Combo in Ovary Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Ovary Cancer Clinical Trial page.